Jaguar Health Inc (JAGX) Quote

IMHO this the most important verbiage from yesterday's PR drop. Jaguar has 2,300 medicinal plants in it's library, which I assume with proper funding could all be researched one day.

"Our team has always recognized and valued the unique and powerful knowledge Indigenous and traditional peoples have about plants, ecosystems, and healing compounds," said Steven King, Ph.D., Jaguar's chief sustainable supply and ethnobotanical research officer and an Advisor to Magdalena. "Jaguar's library of approximately 2,300 medicinal plants from tropical regions - developed over three decades by medicinal tropical scientific strategy team advisors, including ethnobotanists, physicians, pharmacologists, chemists, and experts in neuropharmacology from around the world - comprises a unique asset to drive drug discovery. The plant collection was assembled by teams of experts who conducted primary, first-hand field investigations and plant identification work in rainforest regions around the globe in addition to gathering data about traditional medicinal uses of plants from shamans and other Indigenous healers."

I said this literally yesterday and I'm sure some of you scoffed at me, if you are short JAGX good luck.

Does not really come as a surprise for me, obviously the initial plan (Exhibitors allready sign in months in advance) was to present the ONTARGET results at ASCO. Like that was the plan allready in the summer of 2023...

But than we faced the statistical error that took time.
If data was indeed ready 2 weeks ago (hence imminent), it's obvious they couldn't prepare something for ASCO, especially no full booth. It takes time to get it through regulatory as well.

But, that's why I expect the data release on friday ! It will lure people to the NAPO booth, to talk about the new data release, because it will be big news at ASCO. Since ONTARGET has data for several types of cancer !

At least in my eyes that's the most opportune moment to release it... today or tomorrow

250 000 shares bought yesterday in after hours (Dark pool) , expect fireworks today !

damn it all... just told an acquaintance yesterday that the move that dropped it to $4 was done on very heavy volume and that I was hoping it would stay down there a day or two to finish flushing out folks..

My intention was to double up on my position.. traveling today and didn't have a chance to watch it. Oh well, see what tomorrow morn brings..

Good luck... disclaimer: holding 'some' shares, wanted more. See if I can get some under $5 in the morn.. But dang it all, the way things move so fast in whats called a market now a days..

gauranteed they been sitting on this news today, pre split, along with the p3 results. the sponser is NAPO and that guy is Pravin Chatervidi

https://asco24.myexpoonline.com/exhibitors/exhibitor/779 kind of strange that they took the "make cancer less shitty" banner off and went with the Gelcair banner... I dont think we are going to see p3 at the conference, Gelcair is going to be the big news at ASCO and then p3 will be released either during a presentation or late abstract submission day of presentation... idk i could be wrong but either way with todays news this takes JAGX up as well. I think they want investors confused...

Agreed. I pretty much got out before the R/S as I expected it to drop, but accumalating again now that it seems to be getting close to bottom again. I picked up some around the $4 area today. This stock is way bigger than IHUB so it doesnt really matter what everyone says. It will do its own thing whatever that is.

major move incoming ....... imminent ph3 ASCO #GELCAIR #CROFOLEMER #DIARRYEAH!!!!! first pt now $250 cause my old pt post r/s was 8-9$

#vangaurd 192k+ shares 5/29 $5.39 average

You mean even a positive trial 3 results couldn't stop this diarrhea?
Nothings gonna save this POS

It was constipated give it a few hours lol 🤣👍️

It finally decided to shoot up, like a 🌈 of 💩.

I mean what I'm having fun :D

Lol ok

$4.20 Blaze it

.60 cent by Friday my order ready lol

Nothings gonna save this POS

Pumping and diluting, that's all they do, all while dangling the p3 results, like a carrot on a stick, to suckers like me.

Just another pump piece. The language "if approved".

But for how long ? You really think nobody is going to see that this is a drug with a multi billion dollar potential? At a market capacity of 20 million dollars? With allready products generating revenue?

This price action is a big manipulative joke. Eyes closed, and I will wait till the day comes

shorts in total control.

Exactly, I have never seen a stock being so manipulated on good news. But eventually it will all add oil to the fire. It will explode. Just patiently waiting till that day

Wow. Such great news. I expect $3 today.

The U.S. schizophrenia market is projected to grow to $8.06 billion by 2030, according to a market research report by Market Research Future.1

Neuropsychopharmacology profile analysis shows the Botanical Drug Candidate demonstrates antipsychotic activity and has a mechanism of action distinct from FDA-approved therapies for schizophrenia and other mental conditions that present psychotic symptoms. Magdalena, which is approximately 40-percent owned by Jaguar, is focused on advancing plant-based innovation for patients and on identifying the next generation of plant-based first-in-class agents for treatment of mental health conditions. The Botanical Drug Candidate has a long history of use by traditional healers and may have the potential to be the first in a new class of plant-based antipsychotic compounds.

"Our team has always recognized and valued the unique and powerful knowledge Indigenous and traditional peoples have about plants, ecosystems, and healing compounds," said Steven King, Ph.D., Jaguar's chief sustainable supply and ethnobotanical research officer and an Advisor to Magdalena. "Jaguar's library of approximately 2,300 medicinal plants from tropical regions - developed over three decades by medicinal tropical scientific strategy team advisors, including ethnobotanists, physicians, pharmacologists, chemists, and experts in neuropharmacology from around the world - comprises a unique asset to drive drug discovery. The plant collection was assembled by teams of experts who conducted primary, first-hand field investigations and plant identification work in rainforest regions around the globe in addition to gathering data about traditional medicinal uses of plants from shamans and other Indigenous healers."

https://jaguarhealth.gcs-web.com/news-releases/news-release-details/jaguar-health-executes-out-license-deal-joint-venture-magdalena

Good luck to whoever is shorting JAGX . they're about to become a multi-billion dollar company

wow this company jagx everybody around with multiple reverse splits over the past few years.

So are all the criminal " institutions" that were supposibly going to BUY, once the share price got over $5. All the institutions are shorting the hell out of this also.

Im shorting and confident here...This co is a joke

Another positive is the borrow fee for shorts right now is 407.69% , the highest I've seen since researching JAGX
They seem to have no problem driving this into the ground, even on a positive news day, like today. This will soon reach $3. And i don't even want to imagine what will happen if they don't announce the results at asco....

I never imagined it will go this low after the r/s, given the catalyst, that's why i didn't sell, now my shares are basically worthless, so congrats to crooks for this painful lesson, i hope they get CID, so they can test their pos treatment on themselves.

Of that I have not doubt... just think of how big it would be if there was a real CEO in charge and not this self absorbed dolt who runs Jaguar Health... she has no real public company knowledge and how to use the great positive results she has gotten.

But offcourse, since everyone is waiting for phase 3, it might have a minor effect on the stockprice , that's true! I just want to see the bigger picture...

General diarrhea in dogs + functional diarrhea in humans...

Crofelemer will become very big

Except that the prevalence of functional diarrhea = 4,7% in the total population...

I think a lot of people here don't see it, or don't want to see it. Functional diarrhea = + 6 months ... IMPOSSIBLE to take Imodium (loperamide) for so long. No treatments yet for functional diarrhea.

Crofelemer showing positive results... 4,7% of the total population ! This might be better news than cancer induced diarrhea

Agree... with both statements... showing that it works is why there truly is a bright future for the product... just wonder whey the Phase III cancer trial results are not ready yet...

I agree with what you're saying, I'm just happy to know Crofelemer is proving to be useful. Another positive is the borrow fee for shorts right now is 407.69% , the highest I've seen since researching JAGX

Functional Diarrhea has no baring on the Phase III trial that dealt with Cancer Patients... this is simply for people who seem to get chronic diarrhea.... not going to have much of an effect for the investors waiting on the Phase III trial... notice there is NO mention of the Cancer trial in the text of the release... there is a blurb in the "About" section but its the same blurb they have used for almost a year now.

Yea, P3 results will make JAGX headline news if they're positive :)

https://jaguarhealth.gcs-web.com/news-releases/news-release-details/investigator-initiated-trial-jaguar-healths-crofelemer-yields

https://www.accesswire.com/867976/investigator-initiated-trial-of-jaguar-healths-crofelemer-yields-positive-results-for-functional-diarrhea

Investigator-Initiated Trial of Jaguar Health’s Crofelemer Yields Positive Results for Functional Diarrhea

Float is TINY, any good news (phase 3) will send this right back up.
After the 1:60 r/s fiasco, i'm expecting the worse, so watch out for Lisa &co dilute this before Phase 3 results.

I am not going to fall in love . After phase 3 I will be out for some time. But market capacity will always reflect a part of the future. The future is Mytesi for CID SBS and MVIS , sales for MVIS and SBS will start in 2025 under early patient acces program in Europe. FDA approval for CID (if positive P3) will come in 2025 as well. Canalevia in the meantime, approved for general diarrhea in dogs (+16 million dogs go to the vet for diarrhea / year , in the US and EU alone) ...

Market cap WILL reflect this partly, and than 50 million is a big joke.

Float is TINY, any good news (phase 3) will send this right back up.

BTW, data postponed ? they were clear, you guys just can't read press releases. LISA made a big mistake in november, by thinking she would get the results of PART 1. (impossible, they never unblind a double blinded study for a data readout). PART 2 was finished in november, results would definitely be in 2024.

Second, she told us they faced a statistical error (not so difficult if you collect data from 6 different countries with several investigators).

They hired a biostatistic expert, that previously worked with crofelemer, to solve this problem (hence forthcoming in the PR's). Now, she upgraded to 'imminent'. To me that says, Error is solved, data is ready.

Timber wolf said market cap $50 mill

Nobody said anything about current or future sales.
They don’t have $50 million is sales according to financials.

Last quarter revenues $2,351,000
Net loss $9,368,000

My point was Lisa will dilute another 200 million shares before the year is up.

Right now the market cap it $22.64 million
Yes good results of the phase3 OnTarget Study will make the market cap go up. But when will that day come? It keeps getting postponed to a later date.
FDA approval for cancer induced patients will make market cap go up too.

Gelclair is only at premarket and has been stated to start sales sometime in 3rd quarter. By this time how many more shares will be added and diluted?

Don’t fall in love with Lisa or JAQX.
Remember to take profits when you can.
Lisa will always take profits from the atm

People were expecting after Ontarget results share price in between $5-$10 before RS..Now after RS will this rise to $300-600 per share after the results are out and if they are good..

Market capacity for this drug (IF POSITIVE Phase 3) , of 250 million dollars is absolutely not much. Several biotechs are trading at the same value without any drug with revenue.... We allready have Canalevia and Mytesi, where revenue will increase while more clinical data is incoming, and in Q3 we will add Gelclair !

250 million dollar market cap, equals a PPS of 50 dollars

Actually technical and fundamentals > fomo, momo, herd will take JAGX much higher.

Potential $8.00 to $10.00 by Friday. This super low floater has many positive fundamental catalysts.

Market cap of 50 million? is this a joke? Canalevia alone could have more than 50 million in sales , add to that Gelclair and Mytesi for HIV....

Look at it this way, if you know it is a well known side effect... Why wouldn't doctors prescribe Mytesi automatically with a cancer treatment?

It is maybe not necessary to proceed with the treatment, but why would you let your patients have diarrhea? nobody likes that...

Exactly! JAGX is a great $$$$$ opportunity.

It absolutely does